• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What are Clinical Trials?
    • Become a Clinical Trial Volunteer
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Vtama (tapinarof) cream

AND
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Vtama (tapinarof) cream

  • Profile

Profile

Contact Information

Contact: Dermavant Sciences
Website: www.vtama.com

Currently Enrolling Trials

    Show More

    General Information

    Vtama (tapinarof) cream 1% is an aryl hydrocarbon receptor agonist.

    Vtama is specifically indicated for the topical treatment of plaque psoriasis in adults.

    Vtama is supplied as a cream for topical administration. Apply a thin layer of cream to affected areas once daily. Wash hands after application, unless Vtama cream is for treatment of the hands.

    Mechanism of Action

    Vtama (tapinarof) is an aryl hydrocarbon receptor (AhR) agonist. The specific mechanisms by which VTAMA cream exerts its therapeutic action in psoriasis patients are unknown.

    Side Effects

    Adverse effects associated with the use of Vtama cream may include, but are not limited to, the following:

    • folliculitis
    • nasopharyngitis
    • contact dermatitis
    • headache
    • pruritus
    • influenza

    Clinical Trial Results

    FDA approval of Vtama was based on two multicenter, randomized, double-blind, vehicle-controlled trials in adults with plaque psoriasis (PSOARING 1 and PSOARING 2. These trials were conducted in a total of 1,025 subjects randomized 2:1 to Vtama cream or vehicle cream applied once daily for 12 weeks to any lesion regardless of anatomic location. Baseline disease severity was graded using the 5-point Physician’s Global Assessment (PGA). The majority of subjects had “Moderate” disease (82%), while 10% had “Mild” disease, and 8% had “Severe” disease at baseline. The extent of disease involvement assessed by mean body surface area (BSA), excluding the scalp, palms, and soles, was 8%.

    The primary efficacy endpoint in both studies was the proportion of subjects who achieved treatment success, defined as a PGA score of “Clear” (0) or “Almost Clear” (1) and at least a 2-grade improvement from baseline.

    • PSOARING 1: PGA Treatment Success: 36% for Vtama patients versus 6% for placebo, a 29% treatment difference.
    • PSOARING 2: PGA Treatment Success: 40% for Vtama patients versus 6%, for placebo, a 34% treatment difference.

    Following 12 weeks of treatment, 73 subjects randomized to Vtama achieved complete disease clearance (PGA 0) and had Vtama withdrawn. These subjects were followed for up to 40 additional weeks with a median time to first worsening (PGA ≥ 2 [“Mild”]) of 114 days.

    Approval Date: 2022-05-01
    Company Name: Dermavant Sciences
    Back to Listings

    Upcoming Events

    • 05Dec

      Thriving in Clinical Research – Overcoming Common Challenges as a Site: Part 3 – Site Resourcing

    • 14Apr

      MAGI 2024: The Clinical Research Conference

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Jonathan Seltzer

      Thought Leadership: Remote Patient Monitoring Gives New View of Safety in Cardiac Clinical Trials

    • Quality_Compass-360x240.png

      Ask the Experts: Applying Quality by Design to Protocols

    • Obesity Treatment Patient

      Clinical Trials Need Greater Representation of Obese Patients, Experts Say

    • Modernize-360x240.png

      FDA IT Modernization Plan Prioritizes Data-Sharing, AI, Collaboration and More

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing